Cell and gene therapies have reached clinical and commercial success as evidenced by the steady number of first approvals over the past four years. Drug developers face mounting challenges linked to rapid increases in demand for the complex modalities while also accounting for the need to drive process efficiencies at scale. Working with the right partner, that offers integrated services, can help ease the increasingly common problems with scale, access to high-demand raw material, viral vector production, and quality requirements.
- Things to consider when developing a cell and gene therapy manufacturing plan
- Catalent’s development and manufacturing capabilities for advanced therapies
- How integrated solutions, including analytical and clinical supply, can help expedite therapies to patients